WSJ

### **Press Release**

# EmeritusDX appoints Dr. Vincent Funari, Renowned Genomics and Bioinformatics Expert, as Chief Scientific Officer

Published: Oct. 30, 2023 at 9:00 a.m. ET

The MarketWatch News Department was not involved in the creation of this content.

Dr. Funari will begin his role on October 30th and lead the scientific and innovation strategy for the organization.

LAKE FOREST, Calif., Oct. 30, 2023 /PRNewswire-PRWeb/ -- EmeritusDX, a rapidly growing cancer diagnostic and information company, proudly announces the appointment of Dr. Vincent Funari, Ph.D. to its executive team. Effective October 30th, Dr. Funari will serve as the Chief Scientific Officer, bringing with him an extensive background in genomics and precision medicine.

### Vincent Funari

Previously, Dr. Funari held the position of Chief Scientific Officer at Imagia Canexia Health, where he spearheaded the development of pioneering tumor profiling laboratory developed tests (LDTs) for both clinical and commercial use. Before this role, he contributed significantly as the Chief Scientific Officer at NeoGenomics, overseeing the successful launch of several comprehensive genomic panels(CGP). Additionally, he

WSJ Barron's MarketWatch IBD

care. Finally in his 10 years at Cedars Sinai and UCLA as an associate professor, he coauthored over 35 peer reviewed publications in industry leading journals(eg NEJM, Science, Nature Genetics, Nature Immunology, Cell host and Microbe, etc) with over 5500 citations. He also helped to usher genomics and bioinformatics into precision medicine as a principal educator in Grand rounds and fellowship programs.

Dr. Funari's impressive 20-year career has centered on integrating genomic technologies into precision medicine, particularly concerning hematologic and solid tumors. He is licensed as a Clinical Genetic Molecular Biologist Scientist (CGMBS) by the California Department of Health Care Services.

Robert Embree, Chief Executive Officer of EmeritusDX, expressed the company's excitement: "EmeritusDX is thrilled to have such a well-respected genomics authority like Dr. Funari leading our research and innovation teams. Dr. Funari will be a vital member of the executive team, leveraging years of research expertise, clinical genomics experience, a strong network, and a passion for innovation in precision medicine."

Upon accepting the role, Dr. Funari commented, "I am thrilled and honored to join the Emeritus DX team and be a part of an organization focused on providing first-in-class patient care. We will work diligently to offer a complete and robust menu for the entire cancer care continuum. I am extremely excited to deploy cutting-edge technology to impact the patients with cancer that Emeritus DX serves."

# **About Emeritus DX**

Emeritus DX is a cancer diagnostic and information company. Our expertise is in delivering actionable clinical information. Within our world-class laboratory, we perform testing that guides the diagnosis and treatment of cancer patients. Our partners include hospital and private pathology laboratories, biotechnology companies, academic institutions, contract research and pharmaceutical development organizations, and more. We understand the dependency on our accurate and timely results and our commitment to excellence in this regard is unwavering.

If you would like more information about this topic, please call 800-959-2846 or email contact@emeritusdx.com

View original content to download multimedia:https://www.prweb.com/releases/emeritusdx-appoints-dr-vincent-funari-

WSJ Barron's MarketWatch IBD


3019/0982.html

# SOURCE Emeritus DX

The MarketWatch News Department was not involved in the creation of this content.

Shocking Profit
Singularity Breakthrough
Review Announced by
Real Student (Online
COSMOS Expert) in
September 2023

# **December's Top Banking Offers**



Sponsors of GO BankingRates

Advertiser Disclosure